Results from a recent study published in the CHEST Journal showed that yoga is a cost-effective form of rehabilitation that is as effective as standard progressive muscle relaxation (PMR) programs for patients with chronic obstructive pulmonary disease (COPD). According to the study, yoga programs can be adopted as…
News
In a recent study published in the journal Telemedicine and eHealth, a team led by researchers from Temple University in Philadelphia showed that a digital health application for reporting chronic obstructive pulmonary disease (COPD) symptoms can facilitate early detection and treatment of disease exacerbations. COPD is…
In a new study entitled “The effect of dietary antioxidant on the COPD risk: the community-based KoGES (Ansan–Anseong) cohort”, the authors report that antioxidant vitamins have a beneficial effect on the risk of chronic obstructive pulmonary disease (COPD) and lung function. The study was published in the…
The COPD Foundation and ViiMed recently announced at the European Respiratory Society International Congress in Amsterdam, the launch of COPD360coach, an idea of a CROWDSHAPED event co-hosted by Novartis Pharmaceuticals and the COPD Foundation this last June. The effort was organized by experts from different backgrounds to…
Data analysis of three trials, OTEMTO® 1 and 2 and ENERGITO®, provided new evidence that Spiolto® Respimat® (Boehringer Ingelheim) improves the quality of life for chronic obstructive pulmonary disease (COPD) patients in maintenance therapy, and it offers a greater overall patient well-being and lung function in comparison to commonly…
GlaxoSmithKline (GSK) and Theravance, Inc. recently announced in a press release their plans to file for a joint-supplemental Japanese New Drug Application (sJNDA) for their collaboratively developed chronic obstructive pulmonary disease (COPD) treatment, Relvar® Ellipta® (fluticasone furoate “FF”/vilanterol “VI” or “FF/VI” or Breo Ellipta). The partners aim to submit the application…
Recent data obtained from a study published in the International Journal of Chronic Obstructive Pulmonary Disease entitled “Benzodiazepine use in COPD: empirical evidence from Norway“ highlighted the misuse of benzodiazepine sedatives among COPD patients. The data, which was taken from the Norwegian Patient Register…
Bracket, an electronic Clinical Outcomes Assessments (eCOA) provider, recently announced that the company has completed a key certification along with partner Evidera™ for the EXACT patient daily e-Diary to be used on the Android mobile platform. By reaching this certification milestone, the Bracket eCOA solution is now the only certified provider of this technology for use on…
Theravance Biopharma, Inc. and Mylan MYL recently announced the commencement of a new phase III clinical program to evaluate revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) being developed to treat chronic obstructive pulmonary disease (COPD). The Phase III clinical program involves two replicate, randomized, placebo-controlled, double-blind, parallel-group,…
Minnesota Health Solutions Corporation (MHS) recently announced a partnership with Novu, an SaaS-based consumer engagement platform designed to align consumers and the health care ecosystem. The partnership will provide a digitally-delivered program to motivate and monitor patients with Chronic Obstructive Pulmonary Disorder (COPD), a condition which, along with all chronic lower respiratory…
Recent Posts
- What a chemistry professor’s stinky plant taught me about COPD
- Oxygen tubing brings me breath, clarity, and independence
- Erasing the stigma of supplemental oxygen so that we can breathe again
- New nebulized combo therapy rapidly boosts lung function in COPD
- I’m going forward, but I don’t need to break the sound barrier to be heard